RGLS (Regulus Therapeutics, Inc.) Annual Net Income

Corporate emblem and logo of Regulus Therapeutics Inc. (RGLS)

The retention of key biochemists and FDA experts has ensured R&D stability for Regulus Therapeutics (RGLS), driving an increase in the company's cash profit as reflected on GURU.Markets; the current value is -0.05. This confirms the success of microRNA therapy for treating the brain and kidneys, while strategic alliances with pharma behemoths minimize biological risks in the development of new genetic drugs.

Regulus (RGLS) Company Net Income: for the period 07/04/2022 - 07/05/2025

Analytical breakdowns and data insights for company Regulus Therapeutics Inc. (RGLS)

- stock value and consensus price forecast:
Market Price Regulus|RGLS - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Regulus|RGLS - Real Price to Acquire Entire Company
- book value of equity indicators:
Book Value per Share Regulus Therapeutics|RGLS - Company Book Value|Market Value to Book Value Ratio regulusrx.com|RGLS - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Regulus Therapeutics|RGLS - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Regulus Therapeutics, Inc.|RGLS - Company Total Debt|Debt to Net Assets Ratio Regulus|RGLS - Company Long-Term Liabilities|Amount of Current Liabilities Regulus Therapeutics|Intermediate Coverage Ratio regulusrx.com
- earnings and market multiples details:
RGLS - Net Profit
Summary company analysis:Regulus (RGLS)
Manufactured product of Regulus Therapeutics Inc

Investors are assessing the business resilience of Regulus Therapeutics (RGLS) through net income, which reflects the final revenue balance after deducting all operating and capital expenditures. By analyzing the company's financial results, one can determine how effectively Jay Hagan's management converts raised capital and breakthroughs in renal RNA therapy into actual commercial returns, distinguishing promising scientific developments from a loss-making model.

Key competitors

Company Net Income Tempus AI (TEM)|QGEN (Qiagen N.V.) - Net Profit|IONS - Annual Net Income|Net Income RGEN (Repligen)|Net Profit Avidity Biosciences Inc (RNA)|Company Net Income CRISPR Therapeutics Corp CRSP|GeneDx Corp - Company Net Income|RARE: Net Income|BEAM - Net Profit|Sarepta (SRPT) - Company Net Income|TWST - Net Financial Result|Net Income TXG|NTLA: Final Profit|Net Income STOK (Stoke Therapeutics)|Profit After Payment of Taxes BLFS|Net Profit WVE (Wave Life Sciences Ltd.)|Final Profit MAZE|Sionna Pharma - Net Profit|Company Net Income Prime Medicine Bio|Taysha Gene Therapies (TSHA) - Company Net Income|uniqure.com - Final Profit|MGTX (MeiraGTx) - Net Profit|Net Profit REGENXBIO Inc|Company Net Income Solid Bio (SLDB)|OCGN: Profit After Tax|Net Profit PACB (Pacific Biosciences)|benitec.com (BNTC) - Company Net Income|DSGN: Net Income|RCKT - Net Profit|FDMT (4D Molecular Therapeutics Inc) - Net Income|LXEO: Profit After Payment of Taxes|KRRO (Korro Bio Inc.) - Net Profit|editasmedicine.com (EDIT) - Net Financial Result|Net Profit SLN|Net Income proqr.com PRQR|Company Net Income Codexis CDXS|Net Financial Result Sangamo BioSciences (SGMO)|NAUT - Company Net Income|Final Profit MGX (metagenomi.co)|DTIL: Net Profit|Annual Net Income Generation Bio GBIO|Company Net Income Boundless Bio, Inc|Company Net Income XCUR|Company Net Income Imunon, Inc. (IMNN)|Net Financial Result phiopharma.com|Net Profit MBIO (Mustang Bio)|RNAZ: Company Profit|BNGO - Company Net Income|APDN (Applied DNA Corp) - Company Profit|BLUE: Net Profit|ImmunoPrecise Antibodies Ltd. (IPA) - Net Profit|Company Net Income Omega Therapeutics, Inc.|OMIC: Final Profit|Net Profit SYRS|TBIO - Company Net Income|Net Profit TCON (TRACON Pharmaceuticals)|Annual Net Income unitybiotechnology.com